Shannon Chang

1.3k total citations
37 papers, 928 citations indexed

About

Shannon Chang is a scholar working on Genetics, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Shannon Chang has authored 37 papers receiving a total of 928 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Genetics, 11 papers in Pulmonary and Respiratory Medicine and 8 papers in Molecular Biology. Recurrent topics in Shannon Chang's work include Glioma Diagnosis and Treatment (18 papers), Inflammatory Bowel Disease (8 papers) and Brain Metastases and Treatment (6 papers). Shannon Chang is often cited by papers focused on Glioma Diagnosis and Treatment (18 papers), Inflammatory Bowel Disease (8 papers) and Brain Metastases and Treatment (6 papers). Shannon Chang collaborates with scholars based in United States, Taiwan and Japan. Shannon Chang's co-authors include Kathleen R. Lamborn, Michael D. Prados, Minesh P. Mehta, Nicholas Butowski, Lisa M. DeAngelis, H. I. Robins, Patrick Y. Wen, Lauren E. Abrey, John G. Kuhn and Timothy F. Cloughesy and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and Gastroenterology.

In The Last Decade

Shannon Chang

31 papers receiving 913 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shannon Chang United States 14 635 281 248 208 196 37 928
T. Mikkelsen United States 11 515 0.8× 270 1.0× 220 0.9× 205 1.0× 134 0.7× 21 731
Debra C. LaFrankie United States 10 537 0.8× 200 0.7× 201 0.8× 180 0.9× 120 0.6× 19 701
Elizabeth Cohen‐Jonathan Moyal France 17 508 0.8× 328 1.2× 255 1.0× 195 0.9× 306 1.6× 50 1.1k
Mario Caccese Italy 17 450 0.7× 253 0.9× 224 0.9× 211 1.0× 242 1.2× 70 883
Tim Cloughesy United States 9 431 0.7× 267 1.0× 176 0.7× 142 0.7× 191 1.0× 17 758
Marina Faedi Italy 13 412 0.6× 157 0.6× 213 0.9× 164 0.8× 199 1.0× 27 710
Elizabeth Cohen‐Jonathan‐Moyal France 14 558 0.9× 519 1.8× 202 0.8× 337 1.6× 217 1.1× 25 1.2k
Brian Thiessen Canada 16 687 1.1× 412 1.5× 295 1.2× 244 1.2× 220 1.1× 32 1.2k
L. Scopece Italy 10 539 0.8× 240 0.9× 360 1.5× 157 0.8× 116 0.6× 18 750
Ivan Lolli Italy 13 388 0.6× 158 0.6× 197 0.8× 202 1.0× 190 1.0× 40 672

Countries citing papers authored by Shannon Chang

Since Specialization
Citations

This map shows the geographic impact of Shannon Chang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shannon Chang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shannon Chang more than expected).

Fields of papers citing papers by Shannon Chang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shannon Chang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shannon Chang. The network helps show where Shannon Chang may publish in the future.

Co-authorship network of co-authors of Shannon Chang

This figure shows the co-authorship network connecting the top 25 collaborators of Shannon Chang. A scholar is included among the top collaborators of Shannon Chang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shannon Chang. Shannon Chang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kim, Chae Won, Hyun-Jin Kim, Keun Bon Ku, et al.. (2025). Gut dysbiosis from high-salt diet promotes glioma via propionate-mediated TGF-β activation. The Journal of Experimental Medicine. 222(8). 1 indexed citations
2.
Itzkowitz, Steven H., Yue Jiang, Cristina Villagra, et al.. (2024). Safety of Immunosuppression in a Prospective Cohort of Inflammatory Bowel Disease Patients With a HIstoRy of CancEr: SAPPHIRE Registry. Clinical Gastroenterology and Hepatology. 23(5). 855–865.e5. 5 indexed citations
3.
Haydek, John P., Harold Richardson, Jana G. Hashash, et al.. (2024). S1334 Primary Prophylaxis Reduces Risk of Pouchitis Among Patients with IPAA and Primary Sclerosing Cholangitis. The American Journal of Gastroenterology. 119(10S). S955–S956.
4.
Levine, Irving, et al.. (2024). S1427 A Single Center Experience of Upadacitinib Treatment for Acute Severe Ulcerative Colitis. The American Journal of Gastroenterology. 119(10S). S1023–S1023.
5.
Barnes, Edward L., Laura H. Raffals, Taha Qazi, et al.. (2023). S1120 Vedolizumab Is Effective for the Treatment of Chronic Inflammatory Conditions of the Pouch in a Prospective Multicenter Study. The American Journal of Gastroenterology. 118(10S). S853–S854.
6.
Hong, Simon, Samantha Zullow, Jordan E. Axelrad, Shannon Chang, & David Hudesman. (2020). P087 REAL-WORLD EFFECTIVENESS OF USTEKINUMAB IN ULCERATIVE COLITIS. Gastroenterology. 158(3). S120–S120. 2 indexed citations
7.
Hudesman, David, et al.. (2019). Su1849 – Risk of New Or Recurrent Cancer in Patients with Inflammatory Bowel Disease and Previous Cancer Exposed to Ustekinumab. Gastroenterology. 156(6). S–634. 1 indexed citations
8.
Wen, Patrick Y., Shannon Chang, Kathleen R. Lamborn, et al.. (2014). Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. Neuro-Oncology. 16(4). 567–578. 127 indexed citations
9.
Han, Seunggu J., John D. Rolston, Annette M. Molinaro, et al.. (2014). Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma. Neuro-Oncology. 16(9). 1255–1262. 38 indexed citations
10.
Khayal, Inas S., Scott R. VandenBerg, K. J. Smith, et al.. (2011). MRI apparent diffusion coefficient reflects histopathologic subtype, axonal disruption, and tumor fraction in diffuse-type grade II gliomas. Neuro-Oncology. 13(11). 1192–1201. 28 indexed citations
11.
Clarke, Jennifer, W. K. Alfred Yung, Shannon Chang, et al.. (2011). Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?. Neuro-Oncology. 13(10). 1118–1124. 83 indexed citations
12.
DeGroot, John, Timothy F. Cloughesy, Jeffrey S. Wefel, et al.. (2011). Clinical trial end points for high-grade glioma: the evolving landscape. Neuro-Oncology. 13(3). 353–361. 89 indexed citations
13.
Wen, Patrick Y., Vinay K. Puduvalli, John G. Kuhn, et al.. (2011). Phase I study of vorinostat in combination with temozolomide in patients with malignant gliomas.. Journal of Clinical Oncology. 29(15_suppl). 2032–2032. 4 indexed citations
14.
Essock-Burns, E., Janine Lupo, Soonmee Cha, et al.. (2010). Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma. Neuro-Oncology. 13(1). 119–131. 40 indexed citations
15.
Iwamoto, Fábio M., Kathleen R. Lamborn, H. I. Robins, et al.. (2010). Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro-Oncology. 12(8). 855–861. 166 indexed citations
16.
Wu, Wenting, et al.. (2009). Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma. Neuro-Oncology. 12(2). 164–172. 72 indexed citations
17.
Wen, Patrick Y., Vinay K. Puduvalli, John G. Kuhn, et al.. (2007). Phase I study of vorinostat (suberoylanilide hydroxamic acid) in combination with temozolomide (TMZ) in patients with malignant gliomas (NABTC 04–03). Journal of Clinical Oncology. 25(18_suppl). 2039–2039. 5 indexed citations
18.
Chang, Shannon, et al.. (2004). MicroPET-based pharmacokinetic analysis of the radiolabeled boron compound [18F]FBPA-F in rats with F98 glioma. Applied Radiation and Isotopes. 61(5). 887–891. 15 indexed citations
19.
Chang, Shannon, et al.. (1999). [Relationship between smoking and drinking and herniation of intervertebral disc].. PubMed. 24(1). 20–2. 2 indexed citations
20.
Prados, Michael D., S. Clifford Schold, Alexander M. Spence, et al.. (1996). Phase II study of paclitaxel in patients with recurrent malignant glioma.. Journal of Clinical Oncology. 14(8). 2316–2321. 83 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by T. Mikkelsen Breakdown of academic impact, for papers by Debra C. LaFrankie Breakdown of academic impact, for papers by Elizabeth Cohen‐Jonathan Moyal Breakdown of academic impact, for papers by Mario Caccese Breakdown of academic impact, for papers by Tim Cloughesy Breakdown of academic impact, for papers by Marina Faedi Breakdown of academic impact, for papers by Elizabeth Cohen‐Jonathan‐Moyal Breakdown of academic impact, for papers by Brian Thiessen Breakdown of academic impact, for papers by L. Scopece Breakdown of academic impact, for papers by Ivan Lolli
Rankless by CCL
2026